Erythrodiol

Erythrodiol

Erythrodiol is a naturally occurring pentacyclic triterpenic alcohol found in olives, olive oil, and a wide range of other plants. As an intermediate in the biosynthesis of well-known triterpenoid acids, it occupies a biochemically significant position in plant secondary metabolism. Over the past two decades, growing scientific attention has illuminated a diverse range of biological activities associated with erythrodiol, including anti-inflammatory, antiproliferative, vasorelaxant, antioxidant, and cardioprotective properties. All research to date is preclinical; no human clinical trials specifically evaluating erythrodiol as a dietary supplement have been completed and published.

Identity and Chemical Characterization

Nomenclature and Classification

Erythrodiol bears the systematic IUPAC name Olean-12-ene-3,28-diol, (3β)- and is also known by the synonyms oleanolic alcohol, 3β-erythrodiol, 3β,28-dihydroxyolean-12-ene, and (+)-erythrodiol. Its CAS registry number is 545-48-2, and its molecular formula is C₃₀H₅₀O₂, corresponding to a molecular weight of 442.72 g/mol.

Triterpenoids are subdivided into three principal skeletal families: lupane, oleane, and ursane. Erythrodiol belongs to the oleane (oleanane) family, alongside oleanolic acid and maslinic acid. Its closest structural isomer among triterpenic diols is uvaol, which belongs to the ursane family. Both erythrodiol and uvaol are triterpenic dialcohols present in the minor fraction of virgin olive oil, in olive leaves, and in the drupe of olives, and they possess the same core chemical structure, differing only in the location of a methyl group.

Physical and Chemical Properties

Erythrodiol is a solid at room temperature with a melting point of 230–231 °C. It is soluble in chloroform and insoluble in water, consistent with its highly lipophilic, polycyclic terpenoid backbone. Analytically, it is amenable to both HPLC and GC analysis; it has been used as a working standard for the determination of terpenoids in olive leaves using solid-phase extraction followed by HPLC analysis.

Biosynthetic Origin

Oleanolic acid—and erythrodiol as its direct precursor—is biosynthesized from 2,3-oxidosqualene via cyclization catalyzed by oxidosqualene cyclase (β-amyrin synthase) to produce β-amyrin, followed by three-step oxidation at the C-28 position of the β-amyrin backbone through erythrodiol (28-hydroxy-β-amyrin) and oleanolic aldehyde as reaction intermediates. This oxidation reaction is catalyzed predominantly by cytochrome P450 monooxygenases (CYPs) belonging to the CYP716A subfamily. Thus, erythrodiol sits at a central intersection of the oleanane triterpene pathway, functioning as both a product of β-amyrin oxidation and a substrate for further oxidation to oleanolic acid and maslinic acid.

The primary sterol metabolism precursor 2,3-oxidosqualene is synthesized in the mevalonate pathway, cyclized to β-amyrin by β-amyrin synthase; β-amyrin and erythrodiol then undergo three consecutive oxidation steps at the C-28 position by CYP enzymes to produce oleanolic acid.

Natural Sources and Distribution

Primary Sources

Oleanolic acid, maslinic acid, uvaol, and erythrodiol are the main triterpenes present in olives, olive tree leaves, and virgin olive oil, with their concentration in virgin olive oil depending on the quality of the oil and the variety of the olive tree. The olive tree (Olea europaea L.) is therefore the primary commercial and research source of erythrodiol.

Uvaol, erythrodiol, maslinic acid, oleanolic acid, and betulinic acid are the main triterpenic compounds found in olive fruits, leaves, and oil. Among them, erythrodiol and uvaol can reach over 600 mg/kg oil in pomace olive oil. Pomace olive oil—produced by chemical extraction of the solid residue ("orujo") remaining after mechanical pressing of virgin olive oil—is therefore a particularly rich source of erythrodiol.

Published literature reports erythrodiol concentrations of 26–90 mg/kg in olive oil for conventional virgin olive oil grades, with substantially higher values in pomace fractions.

Other Botanical Sources

Beyond olive, erythrodiol has been isolated from numerous plant genera and families across the world:

• Scorzonera mongolica (Asteraceae): Two erythrodiol triterpene fatty esters—3β-dodecanoyl erythrodiol and 3β-tetradecanoyl erythrodiol—were isolated from Scorzonera mongolica.
• Maytenus ilicifolia (Celastraceae): Four new triterpenoids were isolated from leaves of the Brazilian medicinal plant Maytenus ilicifolia, together with five known triterpenoids, of which only erythrodiol exhibited significant cytotoxicity against KB/S, KB/VJ300, and KU 19-20 cells.
• Conyza canadensis (Asteraceae): 3-β-Erythrodiol has been isolated from Conyza canadensis, where it was found to inhibit MKN-45 human gastric cancer cell proliferation.
• Momordica charantia (bitter melon, Cucurbitaceae): Erythrodiol is among the phytochemicals identified in bitter melon, alongside a battery of other bioactive compounds that contribute to its reported therapeutic potential.
• Larrea tridentata (creosote bush, Zygophyllaceae): Erythrodiol esters (notably 3β-cinnamoyl derivatives) have been reported from this species, which has a long history of use in North American desert communities.

Ursanes and oleananes, including erythrodiol, are among the main triterpene structures found in plants, including many commonly consumed plant foods. This wide botanical distribution reflects the universality of the oleanane biosynthetic pathway across the plant kingdom.

Traditional and Historical Use

Because erythrodiol is a specific molecular constituent rather than a plant or herb in its own right, no traditional medicine system employed it explicitly as an isolated compound. Its traditional relevance derives entirely from the plants in which it occurs naturally.

Olive (Olea europaea) in Mediterranean Traditions

The olive tree has been cultivated and used medicinally throughout the Mediterranean basin for more than three millennia. Olive leaves, olive fruit, and olive oil were all recorded in ancient Greco-Roman medicine, as well as in traditional Arabic, Ayurvedic, and North African healing systems, for purposes including wound healing, management of fevers, and treatment of digestive and inflammatory conditions. The presence of erythrodiol in these preparations was not identified until modern chemical analysis; the bioactive properties attributed historically to olive preparations are now being retroactively investigated in the context of individual molecular constituents, including erythrodiol. Olive oil phenolic components were mainly investigated for potential effects on inflammatory processes related to atherosclerosis since they are powerful antioxidants, and triterpenoid constituents such as erythrodiol contribute to this phytochemical complexity.

Scorzonera Species in Tibetan and Chinese Traditions

Scorzonera mongolica species have been used as food in China, while the same species are used to treat fever, boils, inflammation, and mastitis in Tibetan traditional medicine. The root and fresh shoots of Scorzonera species are recorded in the literature as used for various diseases including arteriosclerosis, and lung, stomach, and kidney disorders. Erythrodiol is among the terpenoids now isolated from these plants that may underlie some of these traditional applications.

Larrea tridentata in North American Traditional Medicine

Larrea tridentata is a perennial shrub used in traditional medicine in northern Mexico and the southern United States to treat infertility, rheumatism, arthritis, colds, diarrhea, skin problems, pain, and inflammation. Erythrodiol-containing esters have been identified as phytochemical constituents of this plant, although the major bioactive compounds attributed to its traditional use are lignans such as nordihydroguaiaretic acid (NDGA).

Maytenus ilicifolia in Brazilian Traditional Medicine

Maytenus ilicifolia, known in Brazil as espinheira-santa, is a plant with a long history of use in Brazilian folk medicine for gastric complaints, ulcers, and as an anticonceptive. Modern phytochemical investigations of its leaves have identified erythrodiol as a constituent with demonstrable cytotoxic activity in vitro, though the contribution of this compound specifically to the plant's traditional uses has not been formally established.

Chemistry: Key Constituents and Structural Relationships

Erythrodiol itself is the key compound under discussion. Its chemical identity and relationships to other bioactive triterpenoids are summarized here.

• Erythrodiol (Olean-12-ene-3β,28-diol): A pentacyclic triterpenic diol with hydroxyl groups at both C-3 and C-28 positions, and a double bond at C-12–C-13. It carries 30 carbon atoms arranged in the oleanane five-ring framework.
• Uvaol: Erythrodiol and uvaol are two triterpenic dialcohols with the same core chemical structure, differing only in the location of a methyl group—erythrodiol belongs to the oleanane skeleton, uvaol to the ursane skeleton. This subtle structural difference has measurable consequences for biological activity.
• Oleanolic acid and maslinic acid: Erythrodiol is synthesized from β-amyrin and is the precursor of oleanolic acid and maslinic acid, which are major pentacyclic triterpenic acids found in the leaves and fruits of the olive tree.
• Fatty acid esters: Two erythrodiol triterpene fatty esters—3β-dodecanoyl erythrodiol and 3β-tetradecanoyl erythrodiol—have been isolated from natural sources, representing naturally occurring esterified forms of erythrodiol.

Mechanisms of Action

Research has identified several distinct molecular and cellular mechanisms through which erythrodiol exerts its biological effects. All mechanism data originate from in vitro cell culture experiments and animal models; no mechanistic human studies have been published.

Pro-Apoptotic and Antiproliferative Mechanisms

Triterpene (erythrodiol) exposure in 1321N1 astrocytoma cells resulted in the production of reactive oxygen species (ROS) with loss of mitochondrial transmembrane potential, correlated with the activation of c-Jun N-terminal kinases (JNK). The presence of catalase reversed the triterpenic diols-induced mitochondrial depolarization, JNK activation, and apoptotic death, indicating the critical role of ROS in the action of these compounds.

In HT-29 human colorectal adenocarcinoma cells, erythrodiol inhibited cell growth with an EC₅₀ value of 48.8 ± 3.7 µM without any cytotoxic effects in a concentration range up to 100 µM. However, exposure of cells for 24 hours to 50, 100, and 150 µM erythrodiol increased caspase-3-like activity by 3.2-, 4.8-, and 5.2-fold over that in control cells. This demonstrates a clear distinction between antiproliferative (growth inhibition without cell death) and proapoptotic effects depending on concentration.

In HepG2 hepatocarcinoma cells, erythrodiol markedly decreased cell viability without changing ROS levels; the concentrations of glutathione and NADPH were significantly reduced, with selective changes in the activity of several antioxidant enzymes: glutathione peroxidase, glutathione reductase, glucose 6-phosphate dehydrogenase, and 6-phosphogluconate dehydrogenase. This suggests a distinct mechanism in hepatic cancer cells, involving disruption of the cellular antioxidant equilibrium rather than direct ROS elevation.

Cholesterol Efflux and ABCA1 Stabilization

Cholesterol efflux from macrophages is an initial step of reverse cholesterol transport. The ATP-binding cassette transporter A1 (ABCA1) is a key transporter for cholesterol efflux, and its increased expression is regarded to attenuate atherosclerosis. Erythrodiol (Olean-12-ene-3β,28-diol) was identified as an ABCA1 stabilizer and revealed its positive influence on cholesterol efflux in THP-1-derived human macrophages. Among nine tested compounds from olive oil, erythrodiol was the sole compound raising ABCA1 protein level (at 10 µM). This study reveals that erythrodiol promotes cholesterol efflux most likely by inhibiting the degradation of ABCA1 protein, without affecting the protein level of other key cholesterol transporters, i.e., ABCG1 and SR-B1.

Vasorelaxation via Endothelial Nitric Oxide

Erythrodiol showed vasorelaxant activities in aortic rings with endothelium pre-contracted by phenylephrine (maximum percentage of relaxation 73.53 ± 6.01%), with almost no relaxant effect on depolarized or endothelium-denuded aortic segments. The relaxation was significantly attenuated by pre-treatment with the NO synthase inhibitor L-NAME. The present results suggest that the mechanism of relaxation is mainly mediated by endothelial production of NO; however, other mechanisms cannot be excluded.

Anti-Inflammatory Mechanisms

Erythrodiol was shown to inhibit 2-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in a model of chronic skin inflammation. Topical administration of erythrodiol (0.5 mg/ear) reduces ear edema and myeloperoxidase (MPO) activity induced by TPA in mice, indicating inhibition of neutrophil-mediated inflammatory responses at the tissue level.

Antifibrotic and Cardioprotective Mechanisms

The effect of erythrodiol and uvaol on angiotensin II-induced proliferation was evaluated in cardiac myofibroblasts from adult rats. The effect on collagen levels induced by angiotensin II was also evaluated. The presence of low doses of both triterpenes reduced the proliferation of cardiac myofibroblasts induced by angiotensin II. Pretreatment with the PPAR-γ inhibitor GW9662 reversed the effect elicited by both triterpenes, implicating PPAR-γ activation as a key mechanism in erythrodiol's antifibrotic action. Erythrodiol and uvaol decreased collagen I and galectin 3 levels induced by angiotensin II in cardiac myofibroblasts.

Hepatic Transcriptional Modulation

Dietary administration of erythrodiol significantly upregulated 68 and downregulated 124 genes at the level of 2-fold change in male ApoE-deficient mice. These genes belonged to detoxification processes, protein metabolism, and nucleic acid-related metabolites. The results give evidence that erythrodiol exerts a hepatic transcriptional role, but this is selective in terms of sex and requires a threshold dose, and also requires APOA1-containing HDL.

Scientific Evidence by Area of Use

Important caveat: All current scientific evidence for erythrodiol's biological effects derives from in vitro (cell culture) and animal model studies. There are no published human clinical trials examining erythrodiol as an isolated compound. All findings below reflect preclinical research only, and extrapolation to human health outcomes is not scientifically warranted at this stage.

Oncology: Antiproliferative and Apoptotic Activity

Colorectal Cancer (In Vitro)

Although olive oil and some of its constituents are reported to have anticarcinogenic activities, erythrodiol had not been assessed in its cell biological functions in detail prior to the 2008 study by Juan et al., who determined its effects on cell growth and apoptosis in human colorectal carcinoma HT-29 cells. The study demonstrated for the first time that, in colon adenocarcinoma cells, erythrodiol exerts antiproliferative and proapoptotic activity. Evidence strength: Single in vitro study; preliminary.

Brain Cancer / Astrocytoma (In Vitro)

In a PLOS One study, erythrodiol and uvaol were tested on the human 1321N1 astrocytoma cell line. Both triterpenes effectively affected cell proliferation as well as cell cycle phases and induced 1321N1 cell death, successfully modulating the apoptotic response and promoting nuclear condensation and fragmentation. Apoptotic rate in erythrodiol-treated cells increased in a dose-dependent manner, from 1.1% to 55.3%. The concentration tested for JNK activation studies was 25 µM erythrodiol. Evidence strength: Single in vitro study in one astrocytoma cell line; preliminary.

Breast Cancer (In Vitro)

It has been reported that erythrodiol has antitumoral effects in leukemic cells, in skin tumor mouse models, and in astrocytoma cells. A subsequent study evaluated cytotoxic activities as well as effects on cell proliferation, cell cycle profile, apoptotic induction, oxidative stress, and DNA oxidative damage in both highly invasive human breast cancer cells (MDA-MB-231) and human epithelial breast cells (MCF10A). Uvaol and erythrodiol showed different effects in normal versus breast cancer cells, despite sharing the same structure except for the location of a methyl group. Evidence strength: Single in vitro study; preliminary; no in vivo confirmation for breast cancer.

Gastric Cancer (In Vitro and Mouse Xenograft)

A study assessed the in vitro and in vivo anticancer and apoptotic activities of 3-β-erythrodiol isolated from Conyza canadensis in MKN-45 gastric cancer cells and a mouse xenograft model, also evaluating effects on cell cycle arrest, ROS generation, and DNA fragmentation—this constituted the first such report on this cancer model. Evidence strength: One in vitro/mouse xenograft study; preliminary; not replicated.

Hepatocarcinoma (In Vitro)

A 2022 study characterized the cytotoxic effects of erythrodiol on human hepatocarcinoma HepG2 cells by studying changes in cell viability, ROS production, antioxidant defense systems, and the proteome. Results revealed that erythrodiol markedly decreased HepG2 cell viability without changing ROS levels, while concentrations of glutathione and NADPH were significantly reduced, with selective changes in several antioxidant enzyme activities. Evidence strength: Single in vitro study; preliminary.

Lymphoma and Multiple Cancer Lines (In Vitro)

Erythrodiol has been shown to induce apoptosis in HT-29 colon carcinoma cells, MDA-MB-231 breast cancer, and U937 lymphoma cells; in the latter two models, apoptosis resulted from extensive DNA damage and activation of the ROS/JNK pathway. Of triterpenoids isolated from Maytenus ilicifolia, only erythrodiol exhibited significant cytotoxicity against KB/S, KB/VJ300, and KU 19-20 cells.

Overall evidence in oncology: Exclusively in vitro and animal-model data. No clinical translation has been established. Effect concentrations (typically 10–150 µM in cell culture) may not be physiologically achievable through dietary intake. Evidence is considered hypothesis-generating at best.

Cardiovascular System

Vasorelaxation (Animal Tissue Studies)

A study by British Journal of Nutrition evaluated a pharmacological property of oleanolic acid and erythrodiol as vasodilatory agents and determined their mechanism of action, studying vasorelaxant effects in isolated thoracic rat aorta. Erythrodiol induces relaxation of isolated rat aortic rings precontracted with phenylephrine (EC₅₀ = 3.38 µM). Triterpenic components in pomace olive oil induce vasorelaxation of the aorta from spontaneously hypertensive rats (SHR), and this effect generally involves endothelial NO. Evidence strength: Isolated tissue (ex vivo rat aorta); no human or in vivo cardiovascular trials.

Cholesterol Efflux and Atherosclerosis Prevention (In Vitro)

Erythrodiol concentration-dependently increases ABCA1 protein level and promotes cholesterol efflux most likely by inhibiting the degradation of ABCA1 protein. These results may provide hints for the molecular mechanisms underlying observations that olive oil consumption is associated with beneficial effects in the context of cardiovascular disease. Evidence strength: Single in vitro study in macrophage cell line; mechanism is plausible but unproven in humans.

Cardiac Hypertrophy and Antifibrotic Effects (In Vitro and Animal)

The natural triterpenes erythrodiol and uvaol exert anti-inflammatory, vasorelaxing, and anti-proliferative effects. To verify potential antifibrotic effects of both triterpenes in vivo, the effect of erythrodiol or uvaol administration (50 mg/kg/day) was explored in mice infused with angiotensin II (1.44 mg/kg/day, 2 weeks). This in vivo mouse study represents the most advanced cardiovascular model to date. Evidence strength: Cell and mouse model data; no clinical evidence.

Anti-Inflammatory Activity

Erythrodiol is related to anti-inflammatory, immunomodulatory, and anti-edematous properties by reducing neutrophil infiltration, as well as an ability to protect from neuroinflammation. These properties are supported by multiple preclinical observations, including the TPA-induced ear edema mouse model. Topical administration of erythrodiol (0.5 mg/ear) reduces ear edema and myeloperoxidase (MPO) activity induced by TPA in mice. Evidence strength: Mouse topical inflammation model and in vitro data only; no human anti-inflammatory clinical trials.

Antioxidant Activity

Olive oil triterpenes, including erythrodiol, are described to possess antioxidant protection, and are considered a natural source of antioxidants that could be useful compounds for the prevention of multiple diseases related to cell oxidative damage. However, special attention has to be paid to the concentrations used, because higher concentrations may lead to cytotoxic or biphasic effects. The observation that erythrodiol depletes glutathione and NADPH in HepG2 cells at higher concentrations underlines this dose-dependency concern. Evidence strength: In vitro only; concentration-dependent and context-specific effects; no human antioxidant trials.

Hepatic Transcriptome Effects

To test hypotheses about the long-term influence of erythrodiol on hepatic transcriptome and its dependence on APOA1-containing HDL, Western diets containing 0.01% of erythrodiol (10 mg/kg dose) were provided to ApoE- and ApoA1-deficient mice, with hepatic RNA-sequencing carried out in male ApoE-deficient mice. When key upregulated transcripts were analyzed in female ApoE-deficient mice, no change was observed. Likewise, no significant variation was observed in ApoA1- or in ApoE-deficient mice receiving doses ranging from 0.5 to 5 mg/kg erythrodiol. These results indicate significant sex- and dose-dependent hepatic gene expression effects that are context-dependent. Evidence strength: Single animal transcriptomics study; highly sex-, dose-, and genotype-specific; not translatable to dietary recommendations.

Body Systems and Health Areas Associated with Erythrodiol

• Cardiovascular system: Erythrodiol is related to several antioxidant, antithrombotic, and vasorelaxant benefits against cardiovascular problems, combined with the ability to reduce cardiac hypertrophy and block profibrotic effects of angiotensin II.
• Oncology (multiple tumor types): Several studies have shown favorable properties of erythrodiol including antiproliferative and proapoptotic actions against colon adenocarcinoma HT-29 cells, histolytic lymphoma (U937) cells, breast cancer, gastric cancer, and astrocytoma.
• Inflammation and immune modulation: Biological activities include anti-inflammatory, immunomodulatory, and anti-edematous properties by reducing neutrophil infiltration, and the ability to protect from neuroinflammation.
• Liver/Hepatic function: Erythrodiol modulates hepatic gene expression and antioxidant enzyme profiles in preclinical models, with effects on detoxification pathways.
• Cholesterol metabolism: Erythrodiol promotes macrophage cholesterol efflux via ABCA1 stabilization, a mechanism relevant to atherosclerosis prevention in in vitro models.

Dosage Forms and Reported Dosages

Erythrodiol is not currently available as a standalone standardized dietary supplement or approved pharmaceutical. It is encountered in three principal contexts: (1) as a naturally occurring dietary constituent via consumption of olive-based foods; (2) as a purified laboratory/analytical standard used in research; and (3) as a constituent of standardized olive-derived extracts under investigation. The following dosages appear in peer-reviewed literature and pertain exclusively to experimental models:

• In vitro (cell culture) concentrations: Antiproliferative effects in HT-29 colorectal cells were observed with an EC₅₀ of 48.8 ± 3.7 µM, with caspase-3 activation studied at 50, 100, and 150 µM. Vasorelaxant effects in isolated aortic tissue were observed with an EC₅₀ of 3.38 µM. ABCA1-stabilizing and cholesterol efflux-promoting effects were observed at 10 µM in THP-1 macrophages. Erythrodiol-induced ROS and apoptosis in breast cancer (MCF-7) cells were reported at 100 µM.
• Topical (mouse model): Topical administration of erythrodiol at 0.5 mg/ear reduced ear edema and myeloperoxidase (MPO) activity induced by TPA in mice.
• Oral animal (mouse, cardiac model): Administration of erythrodiol or uvaol at 50 mg/kg/day was studied in mice infused with angiotensin II for 2 weeks.
• Oral dietary (mouse, transcriptomics study): Western diets containing 0.01% of erythrodiol (10 mg/kg dose) were provided to ApoE- and ApoA1-deficient mice. No significant variation was observed at doses ranging from 0.5 to 5 mg/kg erythrodiol.
• Dietary exposure through olive oil: Erythrodiol and uvaol can reach over 600 mg/kg oil in pomace olive oil, meaning typical human dietary intake through olive oil consumption delivers only trace quantities of the compound; estimated intakes are far below concentrations used in experimental models.

Safety Considerations and Interactions

No formal human toxicology or safety pharmacology studies have been published specifically for erythrodiol as an isolated compound. The following observations derive from the available preclinical literature:

Cytotoxicity and Concentration-Dependence

Olive oil triterpenes including erythrodiol are a natural source of antioxidants that could be useful compounds for the prevention of multiple diseases related to cell oxidative damage; however, special attention has to be paid to the concentrations used, because higher concentrations may lead to cytotoxic or biphasic effects. In HT-29 cells, erythrodiol inhibited cell growth with an EC₅₀ of 48.8 µM without any cytotoxic effects up to 100 µM, but proapoptotic caspase activation was demonstrable at 50–150 µM, suggesting that the line between antiproliferative and cytotoxic concentrations is narrow and dose-dependent.

Antioxidant Enzyme Disruption

In HepG2 hepatocarcinoma cells, erythrodiol markedly decreased cell viability, and significantly reduced concentrations of glutathione and NADPH, with selective changes in the activity of several antioxidant enzymes. These findings, while observed in cancer cells, raise the question of whether erythrodiol at sufficiently high doses could disrupt antioxidant homeostasis in normal hepatic cells.

Sex-Specific Hepatic Effects

Erythrodiol exerts a hepatic transcriptional role, but this is selective in terms of sex and requires a threshold dose. Furthermore, it requires an APOA1-containing HDL. The observation that significant hepatic gene expression changes occurred in male but not female mice suggests potential sex-dependent pharmacodynamics, the implications of which for human populations remain entirely unclear.

Solubility and Bioavailability Limitations

Erythrodiol is soluble in chloroform but insoluble in water, making its oral bioavailability in standard dietary forms a significant scientific concern. The concentrations achieving biological effects in cell culture (typically 10–150 µM) are far above what could plausibly be achieved in human plasma from dietary olive oil consumption. No human pharmacokinetic or bioavailability studies have been published.

No Known Drug Interaction Data

No published literature has specifically examined erythrodiol's interaction with pharmaceutical drugs, cytochrome P450 enzymes in a human clinical context, or other dietary supplements. The hepatic transcriptomics data showing upregulation of CYP2b10, CYP2b9, and CYP2b13 in mouse liver at a dose of 10 mg/kg suggests potential interactions with CYP2B-mediated drug metabolism pathways, though this has not been investigated in humans.

No Regulatory Status as a Standalone Supplement

Erythrodiol has not been evaluated by the United States Food and Drug Administration (FDA), the European Food Safety Authority (EFSA), or the European Medicines Agency (EMA) as a standalone dietary supplement ingredient. It is not listed in the WHO Model List of Essential Medicines or any recognized pharmacopeia monograph as an isolated active substance. It appears in food safety literature only in the context of olive oil quality and composition analysis.

Research Status and Outlook

Triterpene alcohols and acids are multifunctional compounds widely distributed throughout the plant kingdom that exhibit a variety of beneficial health properties, with synthetic analogs of oleanolic acid under clinical evaluation as anti-tumoral therapeutic agents. Erythrodiol, as the immediate biosynthetic precursor to oleanolic acid, shares structural features with those clinically evaluated derivatives, lending biological plausibility to its investigation. However, the field remains at an early preclinical stage. Results from erythrodiol research may provide hints for the molecular mechanisms underlying observations that olive oil consumption is associated with beneficial cardiovascular effects; despite recent advances in studying olive oil and its components, still little is known about the compounds that mediate its cardiovascular protective effects.

The primary research gaps include: absence of human pharmacokinetic data; lack of validated methods for measuring erythrodiol in human plasma at physiologically relevant concentrations; no clinical trials in any indication; uncertainty about whether dietary concentrations achieved through olive oil consumption are sufficient to produce the biological effects observed in preclinical models; and limited understanding of sex-specific effects at the transcriptional and metabolic levels.

References

• Juan ME, et al. "Erythrodiol, a natural triterpenoid from olives, has antiproliferative and apoptotic activity in HT-29 human adenocarcinoma cells." Molecular Nutrition & Food Research, 2008. PubMed PMID 18384095
• Lieber M, et al. "Erythrodiol, an Olive Oil Constituent, Increases the Half-Life of ABCA1 and Enhances Cholesterol Efflux from THP-1-Derived Macrophages." Frontiers in Pharmacology, 2017. PubMed PMID 28659806
• Lieber M, et al. "Erythrodiol, an Olive Oil Constituent, Increases the Half-Life of ABCA1 and Enhances Cholesterol Efflux from THP-1-Derived Macrophages." PMC Article PMC5468437
• Reyes-Zurita FJ, et al. "Natural Triterpenic Diols Promote Apoptosis in Astrocytoma Cells through ROS-Mediated Mitochondrial Depolarization and JNK Activation." PLOS One, 2009.
• Reyes-Zurita FJ, et al. "Natural triterpenic diols promote apoptosis in astrocytoma cells through ROS-mediated mitochondrial depolarization and JNK activation." PubMed PMID 19543395
• Romero C, et al. "Bioactive Properties of the Main Triterpenes Found in Olives, Virgin Olive Oil, and Leaves of Olea europaea." Journal of Agricultural and Food Chemistry, 2013.
• Rodriguez-Rodriguez R, et al. "Potential vasorelaxant effects of oleanolic acid and erythrodiol, two triterpenoids contained in 'orujo' olive oil, on rat aorta." British Journal of Nutrition, 2004.
• Reyes-Zurita FJ, et al. "DIOL Triterpenes Block Profibrotic Effects of Angiotensin II and Protect from Cardiac Hypertrophy." PLOS One, 2012. PMC3402387
• Abuobeid R, et al. "Dietary Erythrodiol Modifies Hepatic Transcriptome in Mice in a Sex and Dose-Dependent Way." International Journal of Molecular Sciences, 2020. PMC7582860
• Rufino-Palomares EE, et al. "Effects of Erythrodiol on the Antioxidant Response and Proteome of HepG2 Cells." Antioxidants, 2022.
• Rufino-Palomares EE, et al. "Effects of Erythrodiol on the Antioxidant Response and Proteome of HepG2 Cells." PMC Article PMC8772852
• Reyes-Zurita FJ, et al. "The differential localization of a methyl group confers a different anti-breast cancer activity to two triterpenes present in olives." PubMed PMID 25412049
• Liu K, et al. "3-β-Erythrodiol isolated from Conyza canadensis inhibits MKN-45 human gastric cancer cell proliferation." Oncology Reports, 2016.
• PubChem. "(+)-Erythrodiol | C30H50O2 | CID 101761." National Institutes of Health, National Library of Medicine.
• ScienceDirect Topics. "Erythrodiol – an overview." Elsevier.
• He X, et al. "A new erythrodiol triterpene fatty ester from Scorzonera mongolica." ResearchGate / Biochemical Systematics and Ecology, 2009.
• Fujisawa M, et al. "High-yield bioactive triterpenoid production by heterologous expression in Nicotiana benthamiana using the Tsukuba system." Frontiers in Plant Science, 2022.
• Yan S-L, et al. "Oleanolic Acid Alters Multiple Cell Signaling Pathways: Implication in Cancer Prevention and Therapy." International Journal of Molecular Sciences, 2017.
• Arellano-García ME, et al. "Phytochemical Compounds and Pharmacological Properties of Larrea tridentata." PMC Article PMC9458016
• Prasad S, et al. "Targeting Inflammatory Pathways by Triterpenoids for Prevention and Treatment of Cancer." Toxins, 2010. PMC3153165